Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



A Sell-the-News Buying Opportunity

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

The likelihood of a sell-the-news event after a biotech releases new data seems to be directly linked to the run-up a biotech has experienced going into the release. So it shouldn't come as much of a shock that Ariad Pharmaceuticals (Nasdaq: ARIA  ) sold off 8.2% yesterday following the release of the abstract for its leukemia treatment ponatinib to be presented at the American Society of Hematology annual meeting next month. The biotech was up 135% this year going into yesterday.

Because, frankly, the data looks pretty good.

Ariad is going after patients that have failed Otsuka's and Bristol-Myers Squibb's (NYSE: BMY  ) Sprycel or Novartis' (NYSE: NVS  ) Tasigna, or have a mutation that doesn't allow them to be treated with those drugs. Of the chronic phase patients who had been assessed three months after starting ponatinib, 42% of patients resistant or intolerant to Sprycel or Tasigna responded to the drug. Patients with the mutation fared even better, with 57% responding.

The phase 2 trial was a single-arm, open-label trial, which means that all the patients got ponatinib and doctors and their patients knew they got the drug. While double-blinded trials comparing a drug candidate with standard therapy or placebo is the best way to tell if a drug works, it's hard to imagine that around half of the patients would start to improve on their own. These are sick patients with few options, after all.

In fact, this phase 2 trial should be enough to gain Food and Drug Administration approval given the unmet need. Seattle Genetics' (Nasdaq: SGEN  ) Adcetris was approved with just phase 2 data for the same reason.

If the full readout of the trial, which is expected in the first half of next year, produces the same solid results at six months, Ariad shouldn't have any problems getting the drug approved.

Keep track of Ariad as it further develops ponatinib by adding it to the Fool's free My Watchlist service. Just click here to get started.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Novartis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 08, 2011, at 4:41 PM, nobiology wrote:

    Brian- you're back, thank goodness. who WAS that other guy trying to write biotech??

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1585974, ~/Articles/ArticleHandler.aspx, 10/28/2016 5:11:33 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
ARIA $8.93 Down -0.38 -4.08%
Ariad Pharmaceutic… CAPS Rating: ***
BMY $51.96 Up +2.67 +5.42%
Bristol-Myers Squi… CAPS Rating: ****
NVS $71.61 Up +0.48 +0.67%
Novartis CAPS Rating: ****
SGEN $49.93 Down -0.40 -0.79%
Seattle Genetics CAPS Rating: ****